Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.90 |
| ▸ | RAB9A | P51151 | 10/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | MLLT1 | Q03111 | 5/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931686 | 0.95 | NPC1 (1.00) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL14160551 | 0.85 | TRPV1 (0.70) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL9911606 | 0.83 | KMT2A (0.66) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL18618367 | 0.82 | MLLT1 (0.95) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL16373728 | 0.81 | NPC1 (0.81) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL17661429 | 0.81 | NPC1 (1.00) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL11931680 | 0.81 | NPC1 (1.00) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL17933816 | 0.81 | NPC1 (0.95) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL15498768 | 0.80 | LMNA (0.66) | NPC1RAB9AKMT2AS1PR1MEN1 | |
| SCHEMBL13902147 | 0.80 | S1PR1 (1.00) | NPC1RAB9AKMT2AS1PR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021183937-A1 | SUBSTITUTED ISOXAZOLES AS SELECTIVE NAV1.7 INHIBITORS FOR PAIN TREATMENT AND METHOD OF PAIN TREATMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-16 | — | — | WO | disclosed |
| US-9221800-B2 | Isoxazole treatments for diabetes | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140315966-A1 | Isoxazole Treatments for Diabetes | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-23 | — | — | US | disclosed |
| US-8722716-B2 | Isoxazole treatments for diabetes | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130178506-A1 | ISOXAZOLE TREATMENTS FOR DIABETES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178506-A1 | ISOXAZOLE TREATMENTS FOR DIABETES | IAPP, GPR119, INSR | NPC1 3557/4885RAB9A 4073/4885KMT2A 4572/4885 |
| US-20140315966-A1 | Isoxazole Treatments for Diabetes | IAPP, GPR119, INSR | NPC1 3557/4885RAB9A 4073/4885KMT2A 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.